Algernon Pharmaceuticals Inc. Announces Strategic Acquisition of NoBrainer Imaging Centers, Inc.

VANCOUVER, British Columbia, May 13, 2025 — In a significant move to expand its footprint in the neurological healthcare sector, Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) has announced the acquisition of NoBrainer Imaging Centers, Inc. (NIC). This acquisition marks a pivotal step for Algernon as it ventures into the Alzheimer’s Disease (AD) diagnostic and treatment market, leveraging its existing expertise in neurological disorders.

The transaction involves Algernon acquiring 100% of the issued and outstanding shares of NIC, granting the company exclusive master franchise and licensing rights to establish AD screening, diagnostic, and treatment centers across Canada and multiple U.S. markets. This strategic move aligns with Algernon’s mission to develop innovative solutions for neurological disorders, particularly Alzheimer’s and Parkinson’s diseases.

Expansion into Alzheimer’s Diagnostic and Treatment

Algernon plans to capitalize on this acquisition by setting up company-owned clinics and offering individual franchise licenses. This dual approach is designed to facilitate rapid expansion, targeting key markets in Canada, Florida, and Los Angeles. The first clinic is slated to open in the fourth quarter of 2025 in the U.S., marking the beginning of Algernon’s foray into the AD diagnostic and treatment space.

The integration of NIC’s advanced PET scan technology into Algernon’s operations is expected to enhance the company’s diagnostic capabilities significantly. This technology will be a cornerstone of the new Alzheimer’s Diagnostic and Treatment Medical Clinics, providing cutting-edge solutions for early detection and management of Alzheimer’s disease.

Financial and Market Implications

As of May 8, 2025, Algernon Pharmaceuticals Inc. closed at a price of 0.085 CAD, with a market capitalization of 2,440,000 CAD. Despite a negative price-to-earnings ratio of -4.14, the acquisition is anticipated to bolster the company’s growth prospects and market position. The strategic expansion into the AD market is expected to diversify Algernon’s revenue streams and enhance its competitive edge in the biotechnology sector.

Forward-Looking Perspective

With its flagship product, NMDA HUNTER, already successfully commercialized in Canada and the United States, Algernon is well-positioned to leverage its existing infrastructure and expertise in neurological disorders. The acquisition of NIC not only complements Algernon’s current offerings but also opens new avenues for growth and innovation in the rapidly evolving healthcare landscape.

As Algernon embarks on this ambitious expansion, stakeholders and investors are keenly watching the company’s progress. The successful integration of NIC’s technology and the establishment of new clinics are expected to drive significant advancements in Alzheimer’s disease diagnostics and treatment, reinforcing Algernon’s commitment to improving patient outcomes in neurological healthcare.

For more information, please visit Algernon Pharmaceuticals Inc.’s official website or contact their investor relations team.